Addex Therapeutics Files 6-K with Press Release
Ticker: ADXN · Form: 6-K · Filed: Oct 29, 2025 · CIK: 1574232
Sentiment: neutral
Topics: filing, press-release, sec-filing
TL;DR
Addex Therapeutics filed a 6-K on Oct 29, 2025, incorporating a press release into SEC filings.
AI Summary
On October 29, 2025, Addex Therapeutics Ltd. issued a press release that is incorporated by reference into their Form 6-K filing. This press release is also being incorporated into their existing registration statements on Form F-3 (Registration No. 333-255089) and Form S-8 (Registration No. 333-255124).
Why It Matters
This filing indicates that Addex Therapeutics is providing updated information to the SEC, which may contain material developments relevant to investors.
Risk Assessment
Risk Level: low — This filing is primarily procedural, incorporating a press release into existing SEC filings, and does not appear to contain new material financial or operational information.
Key Numbers
- 001-39179 — SEC File Number (Identifies the specific SEC filing for Addex Therapeutics Ltd.)
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- October 29, 2025 (date) — Date of press release and filing
- 333-255089 (registration_number) — Form F-3 registration statement
- 333-255124 (registration_number) — Form S-8 registration statement
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a press release issued by Addex Therapeutics Ltd. on October 29, 2025, and to incorporate it by reference into existing SEC filings.
Which registration statements are being updated by this filing?
The press release is being incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) and the registration statement on Form S-8 (Registration No. 333-255124).
What is the filing date of this Form 6-K?
The filing date is October 29, 2025.
What type of company is Addex Therapeutics Ltd.?
Addex Therapeutics Ltd. is classified under the Standard Industrial Classification code 2834, which is Pharmaceutical Preparations.
Where is Addex Therapeutics Ltd. headquartered?
Addex Therapeutics Ltd. is headquartered in Geneva, Switzerland, with its principal executive office located at Chemin des Mines 9, CH-1202 Geneva.
Filing Stats: 272 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2025-10-29 06:35:05
Filing Documents
- f6k_102925.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 6KB
- 0001171843-25-006744.txt ( ) — 13KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] On October 29, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. (c) Exhibit 99.1. Press release dated October 29, 2025 INCORPORATION BY REFERENCE Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd (Registrant) Date: October 29, 2025 /s/ Tim Dyer Tim Dyer Chief Executive Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press release dated October 29, 2025